Xenon Pharmaceuticals Inc. Common Shares (XENE)
XENE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/0001193125-26-076650-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), period ending 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | XENE on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Canada |
| IPO year | 2014 |
| SEC CIK | 0001582313 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | A1 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $7.5M |
| Net income | -$345.9M |
| Operating income | -$373.1M |
| Net margin | -4612.1% |
| Operating margin | -4974.3% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $199.2M |
| Total assets | $633.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 444.4× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-03-12 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-08-06 |
| Latest proxy | DEFA14A | 2026-04-22 |
Source: SEC EDGAR submissions feed, 798 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -6.9% |
| 1 month | -39.7% |
| 3 months | -49.4% |
| Year to date | -24.3% |
| 1 year | -15.2% |
| From 52-week high | -52.2% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| VKTX | Viking Therapeutics Inc. | $26.65 | -5.96% | $3.3B |
| IDYA | IDEAYA Biosciences Inc. | $34.26 | -4.99% | $3.3B |
| AMLX | Amylyx Pharmaceuticals Inc. | $26.85 | -2.29% | $3.4B |
| ARQT | Arcutis Biotherapeutics Inc. | $26.09 | -0.50% | $3.3B |
| PBLS | Parabilis Medicines Inc. | $26.85 | -7.25% | $3.3B |
| ACAD | ACADIA Pharmaceuticals Inc. | $18.62 | -4.07% | $3.2B |
| LEGN | Legend Biotech Corporation | $17.88 | +0.45% | $3.5B |
| OGN | Organon & Co. Common Stock | $13.77 | 0.00% | $3.6B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier